130 related articles for article (PubMed ID: 28006830)
1. [c-MET Oncogene in Renal Cell Carcinomas].
Erlmeier F; Weichert W; Autenrieth M; Ivanyi P; Hartmann A; Steffens S
Aktuelle Urol; 2016 Dec; 47(6):475-479. PubMed ID: 28006830
[TBL] [Abstract][Full Text] [Related]
2. MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.
Macher-Goeppinger S; Keith M; Endris V; Penzel R; Tagscherer KE; Pahernik S; Hohenfellner M; Gardner H; Grüllich C; Schirmacher P; Roth W
Oncotarget; 2017 Jan; 8(1):1046-1057. PubMed ID: 27894094
[TBL] [Abstract][Full Text] [Related]
3. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.
Salvi A; Marchina E; Benetti A; Grigolato P; De Petro G; Barlati S
Int J Oncol; 2008 Aug; 33(2):271-6. PubMed ID: 18636147
[TBL] [Abstract][Full Text] [Related]
4. MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features.
Denize T; Just PA; Sibony M; Blons H; Timsit MO; Drossart T; Jakubowicz D; Broudin C; Morini A; Molina T; Vano Y; Auvray-Kuentz M; Richard S; Mejean A; Gimenez Roqueplo AP; Burnichon N; Verkarre V
Mod Pathol; 2021 Mar; 34(3):647-659. PubMed ID: 32770124
[TBL] [Abstract][Full Text] [Related]
5. Biological significance of c-met over expression in papillary renal cell carcinoma.
Sweeney P; El-Naggar AK; Lin SH; Pisters LL
J Urol; 2002 Jul; 168(1):51-5. PubMed ID: 12050491
[TBL] [Abstract][Full Text] [Related]
6. Mapping of the 7q31 subregion common to the small chromosome 7 derivatives from two sporadic papillary renal cell carcinomas: increased copy number and overexpression of the MET proto-oncogene.
Glukhova L; Lavialle C; Fauvet D; Chudoba I; Danglot G; Angevin E; Bernheim A; Goguel AF
Oncogene; 2000 Feb; 19(6):754-61. PubMed ID: 10698493
[TBL] [Abstract][Full Text] [Related]
7. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.
Lindor NM; Dechet CB; Greene MH; Jenkins RB; Zincke MT; Weaver AL; Wilson M; Zincke H; Liu W
Genet Test; 2001; 5(2):101-6. PubMed ID: 11551094
[TBL] [Abstract][Full Text] [Related]
8. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
[TBL] [Abstract][Full Text] [Related]
9. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype.
Lubensky IA; Schmidt L; Zhuang Z; Weirich G; Pack S; Zambrano N; Walther MM; Choyke P; Linehan WM; Zbar B
Am J Pathol; 1999 Aug; 155(2):517-26. PubMed ID: 10433944
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathology of renal cell carcinoma.
Störkel S
Urologe A; 2004 Sep; 43 Suppl 3():S118-9. PubMed ID: 15164177
[No Abstract] [Full Text] [Related]
12. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Duh FM; Chen F; Kishida T; Glenn G; Choyke P; Scherer SW; Zhuang Z; Lubensky I; Dean M; Allikmets R; Chidambaram A; Bergerheim UR; Feltis JT; Casadevall C; Zamarron A; Bernues M; Richard S; Lips CJ; Walther MM; Tsui LC; Geil L; Orcutt ML; Stackhouse T; Lipan J; Slife L; Brauch H; Decker J; Niehans G; Hughson MD; Moch H; Storkel S; Lerman MI; Linehan WM; Zbar B
Nat Genet; 1997 May; 16(1):68-73. PubMed ID: 9140397
[TBL] [Abstract][Full Text] [Related]
13. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.
Harshman LC; Choueiri TK
Cancer J; 2013; 19(4):316-23. PubMed ID: 23867513
[TBL] [Abstract][Full Text] [Related]
14. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
Albiges L; Guegan J; Le Formal A; Verkarre V; Rioux-Leclercq N; Sibony M; Bernhard JC; Camparo P; Merabet Z; Molinie V; Allory Y; Orear C; Couvé S; Gad S; Patard JJ; Escudier B
Clin Cancer Res; 2014 Jul; 20(13):3411-21. PubMed ID: 24658158
[TBL] [Abstract][Full Text] [Related]
15. Hereditary papillary renal cell carcinoma.
Jacoba IM; Lu Z
Semin Diagn Pathol; 2024 Jan; 41(1):28-31. PubMed ID: 38135585
[TBL] [Abstract][Full Text] [Related]
16. Common pattern of unusual chromosome abnormalities in hereditary papillary renal carcinoma.
Prat E; Bernués M; Del Rey J; Camps J; Ponsa I; Algaba F; Egozcue J; Caballín MR; Gelabert A; Miró R
Cancer Genet Cytogenet; 2006 Jan; 164(2):142-7. PubMed ID: 16434318
[TBL] [Abstract][Full Text] [Related]
17. Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease.
Zhang W; Tan AY; Blumenfeld J; Liu G; Michaeel A; Zhang T; Robinson BD; Salvatore SP; Kapur S; Donahue S; Bobb WO; Rennert H
Cancer Genet; 2016; 209(1-2):11-20. PubMed ID: 26718059
[TBL] [Abstract][Full Text] [Related]
18. MET expression in sporadic renal cell carcinomas.
Choi JS; Kim MK; Seo JW; Choi YL; Kim DH; Chun YK; Ko YH
J Korean Med Sci; 2006 Aug; 21(4):672-7. PubMed ID: 16891811
[TBL] [Abstract][Full Text] [Related]
19. MET as a target in papillary renal cell carcinoma.
Fay AP; Signoretti S; Choueiri TK
Clin Cancer Res; 2014 Jul; 20(13):3361-3. PubMed ID: 24812413
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of renal cell carcinoma and clinical implications.
Rogers CG; Tan MH; Teh BT
Urology; 2005 Feb; 65(2):231-7. PubMed ID: 15708028
[No Abstract] [Full Text] [Related]
[Next] [New Search]
